← Back to screener

Lyell Immunopharma, Inc. LYEL

Rank #2025 · Nasdaq · $0.3B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
36.0
P/E
-1.1
P/B
0.31
ROE
-28.2%
Op. Margin
-190006.2%
Debt Ratio
13%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Average

P/E -1.1x, P/B 0.31x. Ranks in the top 50% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -28.2%. Ranks in the top 92% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 13%. Ranks in the top 10% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 99.8% year over year. Ranks in the top 100% of the universe.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2021$0.0B$-0.1B$-0.1B$0.0B-15538.722334
2022$0.0B$-0.2B$-0.2B$-0.1B-2732.6-178
2023$0.0B$-0.2B$-0.3B$-0.3B-2016.7-36
2024$0.1B$-0.2B$-0.2B$0.9B-220.910
2025$0.0B$-0.2B$-0.2B$0.8B-190006.213

← See the full screener